rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    PLX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      PLX: Elfabrio Estimates Up, Again
      Nov 11Yahoo FinancePLX
      Protalix BioTherapeutics, Inc. Q3 2026 Earnings Call Summary
      Nov 11Yahoo FinancePLX
      Protalix BioTherapeutics Inc (PLX) (Q3 2026) Earnings Call Highlights: Revenue Surges to $21. ...
      Nov 10Yahoo FinancePLX
      Earnings call transcript: Protalix beats Q3 2026 forecasts, but stock slips
      Nov 10Investing.comPLX
      Protalix BioTherapeutics Q3 2026 Earnings Call Transcript
      Nov 10BenzingaPLX
      Protalix: Q3 Earnings Snapshot

      (AP) — Protalix BioTherapeutics Inc. (PLX) on Tuesday reported profit of $4 million in its third quarter.

      Nov 10Yahoo FinancePLX
      Protalix BioTherapeutics to Announce Third Quarter 2026 Financial Results and Business Update on November 10, 2026
      Nov 3Yahoo FinancePLX
      Protalix BioTherapeutics to Present at the Stifel 2026 Healthcare Conference

      Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that Dror Bashan, President and Chief Executive Officer, is scheduled to present at the Stifel 2026 Healthcare Conference. The Conference is being held on November 10-12, 2026 at the Lotte New York Palace Hotel, New York City, NY.

      Oct 26Yahoo FinancePLX
      Protalix at Morgan Stanley conference: rare-disease growth in focus
      Sep 16Investing.comMSPLX
      Wall Street Analysts Are Bullish on Top Healthcare Picks

      Detailed price information for Protalix Biotherapeutics (PLX-A) from The Globe and Mail including charting and trades.

      Sep 10The Globe and MailRZLTPLX
      Protalix BioTherapeutics to Participate in Upcoming September 2026 Investor Conferences

      Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced that Gilad Mamlok, Senior Vice President and Chief Financial Officer, is scheduled to participate in the following two upcoming investor conferences in New York City, New York:

      Sep 8Yahoo FinancePLX
      Protalix Biotherapeutics Earnings Call Signals Strong Momentum

      Detailed price information for Protalix Biotherapeutics (PLX-A) from The Globe and Mail including charting and trades.

      Aug 24The Globe and MailPLX

      This is the newest page. Registered accounts read further back.